KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Share-based Compensation: 2016-2024

Historic Share-based Compensation for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to $429.0 million.

  • Moderna's Share-based Compensation rose 11.61% to $125.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $474.0 million, marking a year-over-year increase of 17.33%. This contributed to the annual value of $429.0 million for FY2024, which is 40.66% up from last year.
  • Latest data reveals that Moderna reported Share-based Compensation of $429.0 million as of FY2024, which was up 40.66% from $305.0 million recorded in FY2023.
  • Over the past 5 years, Moderna's Share-based Compensation peaked at $429.0 million during FY2024, and registered a low of $93.0 million during FY2020.
  • For the 3-year period, Moderna's Share-based Compensation averaged around $320.0 million, with its median value being $305.0 million (2023).
  • Data for Moderna's Share-based Compensation shows a peak YoY spiked of 59.15% (in 2022) over the last 5 years.
  • Over the past 5 years, Moderna's Share-based Compensation (Yearly) stood at $93.0 million in 2020, then skyrocketed by 52.69% to $142.0 million in 2021, then surged by 59.15% to $226.0 million in 2022, then skyrocketed by 34.96% to $305.0 million in 2023, then soared by 40.66% to $429.0 million in 2024.